Back to top
more

Phibro Animal Health (PAHC)

(Delayed Data from NSDQ)

$26.11 USD

26.11
356,504

-0.39 (-1.47%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $26.13 +0.02 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

QGEN Stock to Gain From Expanding Oncology Portfolio via New Alliances

by Zacks Equity Research

QIAGEN expands the oncology portfolio with new MRD testing alliances, setting the stage for personalized cancer care and stock growth.

Zacks Equity Research

Here's Why You Should Retain ICLR Stock in Your Portfolio Now

by Zacks Equity Research

Investors remain optimistic about ICON, driven by its commitment to enhance clinical delivery by integrating AI and impressive strategic pacts.

Zacks Equity Research

LH Stock Rises Following the Expansion of Precision Oncology Portfolio

by Zacks Equity Research

Labcorp expands its precision oncology lineup with new cancer tests and a global diagnostic tool.

Zacks Equity Research

Charles River Stock May Gain From Extended CHDI Research Deal on HD

by Zacks Equity Research

CRL and CHDI Foundation extend their Huntington's disease partnership, boosting integration and global flexibility in drug discovery.

Zacks Equity Research

Abbott Benefits From Libre & Biosimilars Amid FX, Cost Headwinds

by Zacks Equity Research

ABT sees a 21.6% jump in CGM sales and growing global diagnostics demand, while FX and macro pressure temper its outlook.

Zacks Equity Research

Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain?

by Zacks Equity Research

ILMN unveils PromoterAI to decode noncoding genetic variants, aiming to drive breakthroughs in rare disease diagnosis.

Zacks Equity Research

Thermo Fisher Launches New Spectral Flow Cytometer: Stock to Gain?

by Zacks Equity Research

TMO unveils spectral-enabled Attune Xenith Flow Cytometer to streamline workflows and boost research accuracy.

Zacks Equity Research

Here's Why Phibro Animal Health (PAHC) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Alcon Stock Rises Following the FDA Approval of TRYPTYR

by Zacks Equity Research

FDA approves ALC's TRYPTYR, a new dry eye treatment with rapid tear production. The approval is supported by strong Phase 3 trial results.

Zacks Equity Research

Bruker Stock to Gain From the Launch of MOVE-T Liquid Dairy Analyzer

by Zacks Equity Research

BRKR unveils the MOVE-T analyzer to boost quality and efficiency in the dairy industry, setting new standards for precision and reliability.

Zacks Equity Research

Is Bio-Techne Stock the Right Pick for Your Portfolio Now?

by Zacks Equity Research

TECH is gaining ground in cell and gene therapy, and with Ella, while navigating macro hurdles. Is it the right fit for your portfolio today?

Zacks Equity Research

Phibro (PAHC) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Phibro (PAHC) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

PAHC or BSX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PAHC vs. BSX: Which Stock Is the Better Value Option?

Zacks Equity Research

Is Phibro Animal Health (PAHC) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Abbott Stock Gains Following FDA Approval of the Tendyne System

by Zacks Equity Research

ABT wins FDA approval for its Tendyne TMVR system, offering a minimally invasive mitral valve replacement for high-risk patients with severe MAC.

Zacks Equity Research

Illumina's TSO Comprehensive Earns Japan's Approval: Stock to Gain?

by Zacks Equity Research

Japan approves ILMN's TSO Comprehensive, marking a key step forward in global precision oncology adoption and clinical use.

Zacks Equity Research

Prestige Consumer Gains 35.7% in a Year: What's Driving the Stock?

by Zacks Equity Research

PBH stock jumps on the back of brand strength, e-commerce gains and smart acquisitions despite tariff and foreign exchange headwinds.

Zacks Equity Research

TMO Stock Set to Gain From the Launch of New Narcotic Analyzers

by Zacks Equity Research

Thermo Fisher launches new TruNarc analyzers to help law enforcement quickly detect 1,200+ substances, boosting field safety and drug interdiction efforts.

Zacks Equity Research

Insulet Gains 78.5% in a Year: What's Driving the Stock?

by Zacks Equity Research

PODD's shares rise on the back of Omnipod 5's growth, global expansion, and strong Q1 2025 gains despite rising operating costs and macro headwinds.

Zacks Equity Research

Should You Retain Henry Schein Stock in Your Portfolio Right Now?

by Zacks Equity Research

Investors are optimistic about HSIC, owing to the strong performance of its Henry Schein One business.

Vasundhara Sawalka headshot

4 Stocks Trading Near 52-Week High With Room to Rise Further

by Vasundhara Sawalka

Investors target stocks that have been on a bullish run lately. Stocks like DB, HRTG, PAHC and TGI are seeing price strength and the momentum is likely to continue.

Zacks Equity Research

Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock

by Zacks Equity Research

EW's new late-breaking clinical data shows early intervention in AS may slash significant costs and improve patient outcomes.

Zacks Equity Research

Best Growth Stocks to Buy for May 23rd

by Zacks Equity Research

PAHC, GLDD and UIS made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 23, 2025.

Zacks Equity Research

Best Value Stocks to Buy for May 23rd

by Zacks Equity Research

PAHC made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 23, 2025.

Zacks Equity Research

Best Income Stocks to Buy for May 23rd

by Zacks Equity Research

FLNG, MDLZ and PAHC made it to the Zacks Rank #1 (Strong Buy) income stocks list on May 23, 2025.